All In Biotech

Drug Trial Radar · NCT07486310

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Mar 1, 2028

Study completion Jun 1, 2029

Sponsor

Lead sponsor
Guangdong Provincial People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, multicenter, open-label, randomized controlled clinical trial, planned to enroll 30 patients with advanced gastric cancer and peritoneal metastasis. It aims to evaluate the safety and efficacy of systemic therapy plus Pressurized Intra-Peritoneal Aerosol Virus (PIPAV) with VRT106 compared to systemic therapy plus Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC).

Conditions

  • Advanced Gastric Cancer

Interventions

  • Doxorubicin (Adriamycin)Drug

    Doxorubicin (Adriamycin)

  • VRT106Drug

    VRT106

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
  2. Incidence of serious adverse eventsTime frame: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
  3. Eastern Cooperative Oncology Group Performance statusTime frame: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
  4. Surgical complicationsTime frame: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
  5. Postoperative pain score (Visual Analogue Scale/VAS score)Time frame: At the beginning of Cycle 1 (each cycle lasting 28 days), at the beginning of Cycle 2 (each cycle lasting 28 days), and at the beginning of Cycle 3 (each cycle lasting 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.